Owkin has secured a partnership with Boehringer Ingelheim, marking the AI-focused biotech company’s third major pharmaceutical collaboration. The deal underscores growing pharmaceutical industry interest in leveraging artificial intelligence platforms for drug development. Financial terms and specific focus areas of the partnership were not detailed in the announcement.